TABLE 5.

Discrimination for predicting 2-year cause-specific chronic obstructive pulmonary disease (COPD)-related and -unrelated mortality in the PROMISE study^#

Indices	COPD-related 2-year mortality	COPD-unrelated 2-year mortality
BODE index¶	0.86 (0.72–0.99)	0.55 (0.42–0.68)
Updated BODE index¶	0.82 (0.68–0.96)	0.57 (0.44–0.71)
ADO index+	0.84 (0.73–0.95)	0.65 (0.52–0.77)
DOSE index+	0.78 (0.67–0.89)	0.52 (0.39–0.64)
Simplified B-AE-D index	0.87 (0.77–0.98)	0.60 (0.48–0.72)
Simplified B-AE-D-C index	0.89 (0.78–0.99)	0.64 (0.52–0.76)
Optimised B-AE-D index	0.88 (0.78–0.99)	0.61 (0.49–0.73)
Optimised B-AE-D-C index	0.90 (0.79–0.99)	0.65 (0.52–0.77)
Age years	0.59 (0.47–0.70)	0.64 (0.52–0.77)
Adjusted Charlson comorbidity index	0.62 (0.50–0.73)	0.62 (0.50–0.74)

Data are presented as C-statistic (95% CI). PROMISE: Predicting Outcome using Systemic Markers in Severe Exacerbations of Chronic Obstructive Pulmonary Disease; BODE: body mass index, airflow obstruction, dyspnoea, exercise capacity; ADO: age, dyspnoea, airflow obstruction; DOSE: dyspnoea, obstruction, smoking, exacerbation; B: body mass index; AE: severe acute exacerbation of chronic obstructive pulmonary disease frequency; D: modified Medical Research Council dyspnoea severity; C: copeptin.^#: n=460; ^¶: 416 missing values in lung function test or 6-min walking distance; ⁺: 444 missing values in lung function test.